Every 10-Q that Verrica Pharmaceuticals Inc. (VRCA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VRCA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VRCA filings page.
Verrica Pharmaceuticals, a dermatology-focused therapeutics company, reported Q2 2026 revenue of $5.9 million, down from $12.7 million a year earlier as prior results included an $8.0 million Torii milestone; core YCANTH product revenue increased to $5.1 million from $4.5 million. Higher R&D spending on the common warts Phase 3 program and VP‑315, along with expanded commercial infrastructure, drove operating expenses to $19.0 million and a net loss of $13.2 million for the quarter, with a six‑month net loss of $22.8 million.
Cash was $11.2 million at June 30, 2026, with $18.4 million used in operating activities in the first half, leading management to conclude that substantial doubt exists about the company’s ability to continue as a going concern within one year of issuance. A new senior secured PD Credit Agreement provides up to $27.5 million of borrowing capacity, including $12.5 million available at closing, but additional equity, debt or partnership funding is still contemplated. Verrica also recorded a $4.0 million class-action settlement liability and a $2.3 million insurance recovery, resulting in $1.7 million of net legal settlement expense.
Verrica Pharmaceuticals reported first-quarter 2026 revenue of $5.0 million, up from $3.4 million a year earlier, driven mainly by higher YCANTH product revenue of $4.3 million. License and collaboration revenue contributed $0.7 million, largely from its Torii Pharmaceuticals agreement.
The company recorded a net loss of $9.7 million, similar to the prior-year period, and an accumulated deficit of $334.6 million as of March 31, 2026. Cash totaled $20.6 million, with operating activities using $9.2 million of cash in the quarter.
Management states there is substantial doubt about Verrica’s ability to continue as a going concern within one year without additional financing. The company plans to seek new capital through equity or debt financings and partnerships while advancing YCANTH for common warts and its oncology candidate VP-315.
Verrica Pharmaceuticals reported consolidated results for the quarter ended June 30, 2025 showing total revenue of $12.7 million, driven by $8.2 million of license and collaboration revenue and $4.5 million of net product sales of YCANTH (VP-102). The company recorded a small net income of $0.2 million for the quarter versus a large loss in the prior-year period, but a net loss of $9.5 million for the six months ended June 30, 2025.
Cash and cash equivalents declined to $15.4 million from $46.3 million at year-end, and the balance sheet shows total debt, net of discounts and issuance costs, of $37.3 million and a derivative liability of $1.8 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern within one year unless additional financing is obtained; the Credit Agreement requires maintaining at least $10.0 million of liquidity and contains covenants that were partially waived for certain 2025 periods.
Key corporate actions include a 1-for-10 reverse stock split (effective July 24, 2025) and a June 27, 2025 amendment with Torii that accelerated an $8.0 million milestone (paid in July 2025) and sets cost-sharing and future royalty/transfer-price arrangements for a Phase 3 program for common warts.